49 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
The Zacks Analyst Blog Highlights: Exxon Mobil, Oracle, Eli Lilly and Coke http://www.zacks.com/stock/news/883863/the-zacks-analyst-blog-highlights-exxon-mobil-oracle-eli-lilly-and-coke?cid=CS-ZC-FT-press_releases-883863 Apr 22, 2020 - The Zacks Analyst Blog Highlights: Exxon Mobil, Oracle, Eli Lilly and Coke
The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics http://www.zacks.com/stock/news/883840/the-zacks-analyst-blog-highlights-eli-lilly-dexcom-viewray-chemed-and-sage-therapeutics?cid=CS-ZC-FT-press_releases-883840 Apr 22, 2020 - The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics
Is a Surprise Coming for Lilly (LLY) This Earnings Season? http://www.zacks.com/stock/news/883574/is-a-surprise-coming-for-lilly-lly-this-earnings-season?cid=CS-ZC-FT-tale_of_the_tape|earnings_surprise-883574 Apr 22, 2020 - Lilly (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Sanofi (SNY) to Report Q1 Earnings: What's in the Cards? http://www.zacks.com/stock/news/883758/sanofi-sny-to-report-q1-earnings-whats-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-883758 Apr 22, 2020 - Investor focus is likely to be on the impact of the coronavirus outbreak on Sanofi's (SNY) performance when it reports first-quarter results.
Q1 Earnings Scorecard and Analyst Reports for Exxon, Oracle & Eli Lilly http://www.zacks.com/research-daily/882127/q1-earnings-scorecard-and-analyst-reports-for-exxon-oracle-eli-lilly?cid=CS-ZC-FT-research_daily-882127 Apr 21, 2020 - Q1 Earnings Scorecard and Analyst Reports for Exxon, Oracle & Eli Lilly
Can Lilly (LLY) Deliver a Beat in Coronavirus-Hit Q1 Earnings? http://www.zacks.com/stock/news/882090/can-lilly-lly-deliver-a-beat-in-coronavirus-hit-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-882090 Apr 21, 2020 - Investor focus is likely to be on the impact of the coronavirus outbreak on Lilly's (LLY) performance when it reports first-quarter results.
Ericsson (ERIC) to Report Q1 Earnings: What's in the Offing? http://www.zacks.com/stock/news/880321/ericsson-eric-to-report-q1-earnings-whats-in-the-offing?cid=CS-ZC-FT-analyst_blog|earnings_preview-880321 Apr 20, 2020 - Ericsson's (ERIC) first-quarter performance is likely to have benefited from momentum in business led by its strategy to increase investments for technology leadership, including 5G.
5 Top Must-Buy Stocks Set to Beat on Q1 Earnings This Week http://www.zacks.com/stock/news/879995/5-top-must-buy-stocks-set-to-beat-on-q1-earnings-this-week?cid=CS-ZC-FT-analyst_blog|investment_ideas-879995 Apr 20, 2020 - Despite the coronavirus-led economic disaster, five stocks with a favorable Zacks Rank are set to beat Q1 earnings estimates this week.
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year? http://www.zacks.com/stock/news/876251/has-eli-lilly-and-lly-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-876251 Apr 17, 2020 - Is (LLY) Outperforming Other Medical Stocks This Year?
Vanda Begins Enrollment in Study for Severe Coronavirus Infection http://www.zacks.com/stock/news/874470/vanda-begins-enrollment-in-study-for-severe-coronavirus-infection?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-874470 Apr 16, 2020 - Vanda (VNDA) and The Feinstein Institutes for Medical Research initiate enrollment in the phase III ODYSSEY study on tradipitant to treat inflammatory lung injury associated with COVID-19 infection.

Pages: 12345

<Page 2>